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Background: Pulmonary arterial hypertension
is a rare disease with a poor prognosis. Epidemio-
logical data are scarce, particularly in the paedi-
atric population. A registry was recently devel-
oped in order to collect epidemiological data on
patients with pulmonary arterial hypertension
(PAH) in Switzerland. This is the first description
of the paediatric data.
Methods: Paediatric patients aged 0–18 years
with the diagnosis of PAH were enrolled in the
registry from 1999 to 2005 with informed consent
from their parents. Patient characteristics, PAH
aetiology, functional capacity, exercise capacity,
treatments and outcome were among the most
important data collected.
Results: A total of 23 patients (12 male, 11 fe-
male) have been thus far included in the registry.
Median age at time of diagnosis was 3 years
(range 1 month–18 years) and median follow-up
was 3.47 years (range 1 day–12.6 years). PAH aeti -
ologies are diagnosed as idiopathic in 8/23 pa-
tients (34.8%) and associated with congenital
heart diseases in 12/23 (52.2%) or with pul-
monary diseases in 3/23 patients (13.0%). Death
occurred in 1 patient before treatment was initi-
ated. Single treatments include medications with
a calcium channel blocker in 2/23 patients, with
bosentan in 10/23, and with inhaled iloprost in
1/23. Combined therapies include bosentan and
inhaled iloprost in 7/23 patients, bosentan and
sildenafil in 2/23 patients, and bosentan, sildenafil
and inhaled iloprost in 2/23 patients. Additional
oral anticoagulation is given to 14/23 patients and
8/23 patients are on oxygen therapy. NYHA class
at baseline visit was obtained in 22/23 patients 
(4 NYHA 2, 17 NYHA 3 and 1 NYHA 4). Changes
in NYHA class were observed over a 2-year pe-
riod in 3/22 patients who improved from NYHA
3 to NYHA 2. Initial improvement of 6-minute
walk distance was observed in 6/13 patients with a
sustained improvement in 4.
Conclusion: These preliminary results provide
information on the epidemiology of PAH in chil-
dren in Switzerland and demonstrate that most
paediatric patients show stabilisation of the dis-
ease under new treatments. This underscores the
utility of registries for rare diseases in providing
crucial information in the era of new therapies. It
may also help to improve the future medical ap-
proach.
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Summary
Pulmonary arterial hypertension is a rare dis-
ease in childhood associated with a poor progno-
sis if left untreated [1, 2]. The most common
causes of PAH in the paediatric population are id-
iopathic or familial forms, congenital heart dis-
ease with left-to-right shunt, and neonatal lung
diseases. Persistent pulmonary hypertension of
the newborn is a particular form of pulmonary ar-
terial hypertension which will be recorded sepa-
rately. Before the era of new treatments for PAH,
the reported median survival for children was 
10 months after diagnosis [3]. Outcome seemed 
to be worse in children than in adults.
During the last two decades tremendous ad-
vances in understanding of the pathogenesis of
pulmonary vascular disease have been made.
These have led to the introduction of new thera-
pies which have greatly improved patient progno-
sis and survival. 
However, epidemiological data are still
scarce, especially in the paediatric population.
Since 1999 a Swiss registry for patients with pul-
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monary arterial hypertension has been launched
under the guidance of the Swiss Society for Pul-
monary Hypertension [4]. Included in the registry
are all forms of PAH except the persistent pul-
monary hypertension of the newborn. In agree-
ment with the Swiss Society for Pulmonary Hy-
pertension some data were entered retrospec-
tively. Cooperation between all the specialised
centres in Switzerland has made it possible to in-
clude all paediatric patients presenting with PAH
in this registry and collect epidemiologic data. 
Methods
Paediatric patients from age 0–18 years with the di-
agnosis of pulmonary arterial hypertension of all aetiolo-
gies except persistent pulmonary hypertension of the
newborn were enrolled in the registry from 1999–2005
with informed consent from the parents. The registry is a
national multicentre, observational non-interventional
programme. The patients were enrolled after diagnosis or
when therapy was initiated or intended. Thus some pa-
tients have baseline visits long before enrolment in the
registry and were entered retrospectively (in agreement
with the Swiss Society for Pulmonary Hypertension).
The data collected in the registry include patient charac-
teristics, pulmonary arterial hypertension aetiology, pa-
tient’s vital signs, right heart catheter data, echocardio-
graphic data, functional capacity, exercise capacity, treat-
ments and outcome. The data presented are a description
of the data collected in the registry. Because of the small
patient numbers and the heterogeneity of the patients, no
statistical analyses were performed.
Patient CHD, Operation Age at PAH at time 
other diagnosis operation of operation
1 d-TGA, VSD Balloonatrioseptostomy, 1day No
Pulmonary artery banding, 1 week
Arterial switch, Debanding, VSD closure 4 months
2 d-TGA Palliative Senning, partial VSD closure 15 months Yes
3 AP window AP window closure 7 years Yes
4 AVSD No
Down syndrome
5 VSD, VSD closure 7 months Yes
Down syndrome
6 VSD, No
Down syndrome
7 VSD No
8 VSD Yes 3 years No
9 VSD No
10 VSD Yes 10 years Yes
11 ASD sinus No
venosus type
12 PDA No
Abbreviations: CHD = congenital heart disease, PAH = pulmonary arterial hypertension, d-TGA = 
Transposition of the great arteries, VSD = ventricular septal defect, Senning operation = atrial switch 
operation, AP window = aortopulmonary window, AVSD = atrioventricular septal defect, ASD = atrial 
septal defect, PDA = patent ductus arteriosus.
Table 1
Figure 1
Changes in 6 minute
walk distance in pa-
tients who did at
least 3 tests (first,
best and last). First
test was not always
at baseline examina-
tion.
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During the 7-year observation period 23 pae-
diatric patients were included in the Swiss PAH
registry. The gender distribution was 12 male and
11 female patients. Age at the time of diagnosis of
pulmonary arterial hypertension was 1 month to
18 years, with a median of 3 years. The follow-up
period was 1 day to 12.6 years with a median of
3.47 years. 
Of these 23 patients all but one are alive. One
patient died before treatment was instituted.
The aetiology of PAH was idiopathic in 8/23
patients (34.8%). PAH associated with congenital
heart disease (CHD) with left-to-right shunt was
found in 12/23 patients (52.2%) and associated
with a pulmonary disease in 3/23 patients
(13.0%). 
Patients with CHD displayed the following
cardiac malformations: transposition of the great
arteries (TGA) with additional ventricular septal
defect (VSD) in 2/12 patients, aortopulmonary
window in 1/12 patients, atrioventricular septal
defect (AVSD) in 1/12 patients, VSD in 4/12 pa-
tients, atrial septal defect (ASD) of the superior
sinus venosus type in 1/12 patients and patent ar-
terial duct (PDA) in 1/12 patients. Down syn-
drome was diagnosed in 3/12 children (1 with
AVSD, 2 with VSD). Heart surgery was per-
formed in 6/12 children. In 2 children PAH was
not present before surgery, 3 had PAH which was
not considered fixed PAH and 1 patient had fixed
PAH. In this patient a palliative Senning opera-
tion was performed to help decrease  hypoxaemia
and enhance quality of life. 6/12 children had
marked pulmonary vascular disease and they were
not considered suitable for cardiac surgery (ta-
ble 1).
By the end of the observation period all the
paediatric patients alive were on a specific treat-
ment. 12/22 patients were on a single medication
and 10/22 on combined medications. Single treat-
ments included calcium channel blocker in 2/22
patients, the dual endothelin receptor blocker
bosentan (Tracleer®) in 9/22 patients, and inhaled
iloprost (a prostacyclin analogue) in 1/22 patients.
Combined treatments included bosentan and in-
haled iloprost in 6/22 patients, bosentan and
sildenafil (a phosphodiesterase type V inhibitor)
in 2/22 patients, and bosentan, sildenafil and in-
haled iloprost in 2/22. 14/22 patients were on oral
anticoagulation and 8/22 received oxygen ther-
apy.
The functional classes were assessed in 22/23
patients at their first visit. 4/22 patients were in
NYHA Class 2, 17/22 in NYHA Class 3, and 
1/22 in NYHA Class 4. Over a period of 2 years
3/22 patients changed NYHA class from class 3 to
class 2.
Exercise capacity was assessed by 6-minute
walk distance, which was measured according to
the ATS Guidelines [5]. Interpretation of this test
is difficult during childhood, however, since no
normal values exist for age and gender, especially
in small children. In some patients baseline values
are lacking due to their too young age at baseline
examination. Nevertheless, in 6/13 patients an
initial improvement in 6-minute walk distance
was noted and in 4 patients this improvement was
sustained (fig. 1).
Results
Discussion
These paediatric data are the first data to be
extracted from the Swiss Registry for PAH. Be-
cause of the small number of patients, only a de-
scriptive analysis of the epidemiological data was
performed. Nevertheless, these data are the first
available information on the epidemiology of
PAH in the paediatric population of a single coun-
try. 
The data collected are very heterogeneous.
This may be related to the different aetiologies of
PAH entered in the registry and may be specific to
paediatric PAH. Some data were entered retro-
spectively and this also explains the heterogeneity,
since not all data were available for all patients.
The therapies in use at the end of the follow-
up period and their combination were highly het-
erogeneous. A possible explanation is the time
when the children were included, a period in
which several new therapies became available and
thus were introduced into the paediatric thera-
peutic armamentarium. In the beginning only cal-
cium channel blockers and prostacyclin analogues
were available. Bosentan and sildenafil became
available during the follow-up period. In the re-
sults presented only the therapies at the end of the
follow-up period are described. During follow-up
therapy was adapted or added according to the pa-
tients’ clinical evolution.
During the follow-up period only 1 patient
died. This suggests that survival has improved
under the therapies presently in use, as compared
to data published 16 years ago [3].
The data show that many patients undergo
stabilisation of their disease under the currently
available treatments [6]. A few patients even
showed some improvement in their functional
and exercise capacity. 
However, interpretation of exercise capacity
by 6-minute walk distance remains difficult in
children. No normal values currently exist, espe-
cially for small children [7]. Hence the 6-minute
walk distance of a child with PAH cannot be reli-
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ably compared with values in healthy children of
the same age group. Further, in children the 6-
minute walk distance most probably depends on
age, height, weight, muscle mass and body mass
index, and will change as childhood advances. In
adults too it has been shown that walk distance is
dependent on age, weight and height [8]. Thus an
improvement in walk distance in children with
PAH cannot be ascribed to successful treatment
alone. However, the results of serial 6-minute
walk tests in a single patient can provide informa-
tion on stabilisation or deterioration of the dis-
ease course, and thus may be highly informative
and helpful during follow-up of a single patient.
A 6-minute walk test was not possible in all
children, the main limitation being the minimum
age at which a 6-minute walk test can be per-
formed (approximately 4–5 years). Moreover, in
some children PAH was diagnosed and treatment
initiated before they could walk. The 6-minute
walk test was therefore interpreted in patients
who had done at least 3 tests.
The patients entered in our registry display
PAH of three different aetiologies, congenital
heart disease with left-to-right shunt, idiopathic,
and associated with pulmonary disease. Patients
with unoperated congenital heart diseases pre-
senting with Eisenmenger syndrome appear to
have a different disease course with better survival
[9, 10]. On the other hand, patients with an un-
derlying congenital lung disease and in many
cases malformations of the lung tissue appear to
have a poorer outcome and a lesser response to
medical therapies. Data emerging from the reg-
istry in the future may provide detailed informa-
tion on the outcome of PAH of different aetiolo-
gies.
Data from registries for rare diseases may
provide important information concerning not
only currently available but also newly licensed
therapies. In the future the use of a registry of this
kind may also help to improve the overall medical
management of paediatric PAH.
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